Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 48, Issue 2, 2003, Pages 63-68

  MacNeill, Colin ^a   Weisz, Judith ^a   Carey, J Christopher ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Candida albicans; Fluconazole; Vulvovaginitis

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ADULT; ARTICLE; CANDIDA ALBICANS; FEMALE; FUNGUS CULTURE; FUNGUS ISOLATION; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT FAILURE; VAGINA CANDIDIASIS;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; COHORT STUDIES; DRUG RESISTANCE, FUNGAL; FEMALE; FLUCONAZOLE; FOLLOW-UP STUDIES; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; TREATMENT OUTCOME; VULVOVAGINITIS;

EID: 0037327517     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Horowitz BJ: Mycotic vulvovaginitis: A broad overview. Am J Obstet Gynecol 1991;165:1188-1192
2. Haefner HK: Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol 1999;42:184-195
3. Foxman B, Barlow R, D'Arcy H, et al: Candida vaginitis: Self-reported incidence and associated costs. Sex Transm Dis 2000;27:230-235
4. Dun E: Antifungal resistance in yeast vaginitis. Yale J Biol Med 2000;72:281-285
5. Sobel JD, Faro S, Force RW, et al: Vulvovaginal candidiasis: Epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol 1998;178:203-211
6. Sobel JD, Kapernick PS, Zervos M, et al: Treatment of complicated Candida vaginitis: Comparison of single and sequential doses of fluconazole. Am J Obstet Gynecol 2001;185:363-369
7. Frega A, Gallo G, Di Renzi F, et al: Persistent vulvovaginal candidiasis: Systemic treatment with oral fluconazole. Clin Exp Obstet Gynecol 1994;21:259-262
8. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1-8
9. Sobel JD, Ohmit SE, Schuman P, et al: The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001;183:286-293
10. Marr KA, Lyons CN, Ha K, et al: Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother 2001;45:52-59
11. Candido RC, Toloi MR, Franceschini SA, et al: In vitro activity of antimycotic agents determined by E-test method against vaginal Candida species. Mycopathologia 1998;144:15-20
12. Nyirjesy P, Seeney SM, Grody MH, et al: Chronic fungal vaginitis: The value of cultures. Am J Obstet Gynecol 1995;173:820-823
13. Otero L, Fleites A, Mendez FJ, et al: Susceptibility of Candida species isolated from female prostitutes with vulvovaginitis to antifungal agents and boric acid. Eur J Clin Microbiol Infect Dis 1999;18:59-61
14. Newman SL, Flanigan TP, Fisher A, et al: Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis 1994;19:684-686
15. Lynch ME, Sobel JD, Fidel PL Jr: Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol 1996;34:337-339
16. Lynch ME, Sobel JD: Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol 1994;32:267-274
17. Sobel JD, Vazquez JA: Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. Clin Infect Dis 1996;22:726-727
18. De Bernardis F, Arancia S, Morelli L, et al: Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis 1999;179:201-208
19. Shah DT, Glover DD, Larsen B: In situ mycotoxin production by Candida albicans in women with vaginitis. Gynecol Obstet Invest 1995;39:67-69
20. Lo HJ, Kohler JR, DiDomenico B, et al: Nonfilamentous C albicans mutants are avirulent. Cell 1997;9:939-949
21. Witkin SS, Jeremias J, Ledger WJ: Vaginal eosinophils and IgE antibodies to Candida albicans in women with recurrent vaginitis. J Med Vet Mycol 1989;27:57-58
22. Barousse MM, Steele C, Dunlap K, et al: Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis 2001;184:1489-1493
23. Barchiesi F, DiFrancesco LF, Scalise G: In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. Antimicrob Agents Chemother 1997;41:1812-1814